MONSANTO COMPANY Sample Clauses

MONSANTO COMPANY. By: Title: Each Guarantee shall be dated the date of the Security upon which it is endorsed. Reference is made to Article Fifteen for further provisions with respect to the Guarantees.
Sample 1
AutoNDA by SimpleDocs
MONSANTO COMPANY. By: ------------------------- Name: Title: PHARMACIA CORPORATION
Sample 1
MONSANTO COMPANY. Xxxxxxx X. Xxxxxxxxxx -------------------------
Sample 1
MONSANTO COMPANY. By: Terrell K. Crews Title: Exexxxxxx Xxxx Xxxxident and Chief Financial Officer ATTEST: -------------------------------- STATE OF MISSOURI ) ) COUNTY OF ST. LOUIS ) On this 15th day of November, 2002, before me the undersigned, a Notary Public, in and for the County and State aforesaid, personally appeared Terrell K. Crews, to me known to be the person described in anx xxx xxxxxxxx the foregoing instrument, and acknowledged that he/she executed the same as his/her free act and deed. IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in St. Louis, the day and year last above written. ---------------------------------------------- Notary Public in and for said County and State My Commission Expires: -------------------------- EXHIBIT C FORM OF SOLUTIA LETTER OF CREDIT IRREVOCABLE LETTER OF CREDIT NO.____________________ DATE_____________________ Monsanto Company Attn: General Counsel 800 North Lindbergh Boulevard St. Louis, MO 63167 To Whom It May Coxxxxx: Xx xxx xxxxxxx xx Xxxxxxx, Xxx. ("Xxxxxxx") we, (Name and Address of Bank), have opened an IRREVOCABLE LETTER OF CREDIT in your favor for $ 20,000,000.00 U.S. Dollars, available by your drafts at sight. We warrant to you that all your drafts under this IRREVOCABLE LETTER OF CREDIT will be duly honored upon presentation of your draft on us at (Address of Bank) on or before the expiration date or on or before any automatically extended date as set forth below. Any draft(s) drawn by you under this Letter of Credit shall be accompanied by your written certification that you have procured the execution of a bond in the amount of $71,433,900.00 at the request of Solutia and that any one or more of the following exists: (i) Claims have been made by SAFECO Insurance Company of America ("Safeco") against you with respect to the bond posted by Safeco ("Safeco Bond") in favor of Monsanto Company relating to the Commonwealth of Pennsylvania, Department of General Services et. al., v. United States Mineral Products et. al., No. 284 M.D. 244 M.D. (Pennsylvania Commonwealth Court) ("Pennsylvania Litigation"); (ii) Claims have been made by Safeco against any letter of credit or other collateral posted by you in order to secure your performance of the Safeco Bond; (iii) An agreement has been duly executed by the parties to the Pennsylvania Litigation settling any claims at issue, or arguably at issue, in the Pennsylvania Litigation and Solutia has not paid the required settlement amount within ...
Sample 1
MONSANTO COMPANY. By: -------------------------------- Title: -----------------------------
Sample 1
MONSANTO COMPANY. By -------------------------------------------- Title: By -------------------------------------------- Title: ADVANCES AND PAYMENTS OF PRINCIPAL ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- Date Amount of Advance Amount of Principal Unpaid Principal Notation Paid or Prepaid Balance Made By ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ---------------------- ------------------------- ---------------------- ----------------------- ---------------------- ----------------...
Sample 1
MONSANTO COMPANY. By ------------------------------------------ Title: By ------------------------------------------ Title: EXHIBIT D - FORM OF ASSUMPTION AGREEMENT Dated: Monsanto Company 800 North Lindbergh Boulevard St. Louis, Missouri 63167 Atxxxxxxx: Xxxxx Xxxxxxxxx Xxxxxxx XXXxxxxx Xxxxx Xxxx, N.A., as Agent 1111 Fannin Street, 10th Floor Houston, Texas 77002 Attentxxx: Xxx Tjahjono Ladies and Gentlemen: Reference is made to the 000-Xxx Xxedit Agreement dated as of March 11, 2005 (as amended or modified from time to time, the "Credit Agreement") among Monsanto Company, a Delaware corporation (the "Borrower"), the Lenders (as defined in the Credit Agreement), JPMorgan Chase Bank, N.A., as agent for the Lenders (the "Agent"), J.P. Morgan Securities Inc. and Citigroup Global Markets Inc., as jxxxx xxxx xrrangers and co-bookrunners, Citibank, N.A., as syndication agent, and ABN AMRO Bank N.V., The Bank of Tokyo-Mitsubishi, Ltd., Chicago Branch and Bank of America, N.A., as co-documentation agents. Terms defined in the Credit Agreement are used herein with the same meaning. The undersigned proposes to become an Assuming Bank pursuant to Section 2.17 of the Credit Agreement and, in that connection, hereby agrees that it shall become a Lender for purposes of the Credit Agreement on [insert applicable Termination Date] and that its Commitment shall as of such date be $ .
Sample 1
AutoNDA by SimpleDocs
MONSANTO COMPANY. By: ------------------------------------- Authorized Officer Accepted: [Name and Signature of Agent] Schedule to Annex I Title of Purchased Securities: Medium-Term Notes, Series D Aggregate principal amount: $ [Denominations] [Price to Public:] Purchase Price by [the Agent]: ---% of the principal amount of the Purchased Securities[, plus accrued interest from -------- to --------] [and accrued amortization, if any, from --------- to ----------] Method of and specified funds for payment of purchase price: Indenture: Indenture, dated as of August 1, 1990, between the Company and The Chase Manhattan Bank (National Association), as Trustee.
Sample 1
MONSANTO COMPANY. Case No. 1:20-cv-01085-MN (N.D. Cal.) (“the Action”).
Sample 1

Related to MONSANTO COMPANY

  • Company The term “

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Limited Liability Company Agreement The Member hereby states that except as otherwise provided by the Act or the Certificate of Formation, the Company shall be operated subject to the terms and conditions of this Agreement.

  • Western will as requested by the Manager oversee the maintenance of all books and records with respect to the investment transactions of the Fund in accordance with all applicable federal and state laws and regulations, and will furnish the Directors with such periodic and special reports as the Directors or the Manager reasonably may request.

Time is Money Join Law Insider Premium to draft better contracts faster.